A clinical-stage biotech developing new drugs to cure chronic hepatitis B, with its lead candidate Vebicorvir already through Phase 2 trials.
Money comes from partnership deals with BeiGene, Arbutus Biopharma, and Antios Therapeutics, plus licensing fees—but revenue is tiny (USD 0.07B in 2025) and the company still loses money, so it's not self-funding yet.
Its HBV pipeline and partnerships with BeiGene and Arbutus create some barriers, but the field is crowded with bigger players like Gilead and Roche, and clinical failure could erase the advantage.
Key events, in time order
Two Zacks reports confirm ASMB's inclusion, indicating positive analyst rating
None yet
None yet
Assembly Biosciences is mentioned in a biotech/pharma stock overview, indicating it's part of a generally positive sector performance.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
